DIPEPTIDYL PEPTIDASE-IV INHIBITORY ACTIVITIES OF MEDICINAL PLANTS: TERMINALIA ARJUNA, COMMIPHORA MUKUL, GYMNEMA SYLVESTRE, MORINDA CITRIFOLIA, EMBLICA OFFICINALIS
Objective: The present study was designed to screen the dipeptidyl peptidase-IV (DPP-IV) inhibitory ability of hydroalcoholic extracts of Terminalia
arjuna, Commiphora mukul, Gymnema sylvestre, Morinda citrifolia, and Emblica officinalis and compare their inhibitory activity with the synthetic
DPP-IV inhibitors (Sitagliptin and Vildagliptin). The aim of the study was to identifying indigenous sources of DPP-IV inhibitors for the management
of type II diabetes mellitus as alternatives to their synthetic counterparts.
Methods: The hydroalcoholic extract of T. arjuna, C. mukul, G. sylvestre, M. citrifolia, E. officinalis and synthetic DPP-IV inhibitors (Sitagliptin and
Vildagliptin) were tested in vitro for DPP-IV inhibitory activity.
Results: The DPP-IV inhibitory activity of synthetic drugs Vildagliptin was found to be 90.42Â±7.84% and Sitagliptin 84.67Â±8.21%. The DPP-IV
Inhibitory activity of T. arjuna was found to be 83.39Â±7.58%, C. mukul: 92.97Â± 8.45%, G. sylvestre: 16.98Â±1.69%, M. citrifolia: 24.64Â±2.24%, and
E. officinalis: 85.95Â±7.16%. C. mukul extract showed superior inhibitory activity than reference standard drugs (Sitagliptin and Vildagliptin).
Conclusion: C. mukul, T. arjuna, and E. officinalis extracts possess significant DPP-IV Inhibitory activity while G. sylvestre and M. citrifolia failed to
markedly inhibit DPP-IV enzyme.
Keywords: Type II diabetes mellitus, Dipeptidyl peptidase-IV inhibitors, Plant extracts, In vitro assay.
1. Drucker DJ. Enhancing incretin action for the treatment of Type 2
diabetes. Diabetes Care 2003;26(10):2929-40.
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev
3. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like
peptide-1 by human plasma in vitro yields an N-terminally truncated
peptide which is a major endogenous metabolite in vivo. J Clin
Endocrinol Metab 1995;80:952-7.
4. Lambeir AM, Durinx C, ScharpÃ© S, De Meester I. Dipeptidyl-peptidase
IV from bench to bedside: An update on structural properties, functions,
and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci
5. Fredenrich A, Palle S, Canivet B. Dipeptidyl peptidase inhibitors:
A new step towards normoglycemia. Open Endocrinol J 2009;3:16-21.
6. Matteucci E, Giampietro O. Dipeptidyl peptidase-4 inhibition:
Linking chemical properties to clinical safety. Curr Med Chem
7. Nicolau Ramis J, Masmiquel Comas L. The new antidiabetic agents
in the firing line. safety reasons or witch hunt?. Endocrinol Nutr
8. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4
inhibitors and pancreatitis risk: A meta-analysis of randomized clinical
trials. Diabetes Obes Metab 2014;16(1):48-56.
9. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis,
pancreatic, and thyroid cancer with glucagon-like peptide-1-based
therapies. Gastroenterology 2011;141(1):150-6.
10. Yogisha S, Raveesha KA. Dipeptidyl peptidase IV inhibitory activity of
Mangifera indica. J Nat Prod 2010;3:76-9.
11. Bharti SK, Sharma NK, Kumar A, Krishnan S, Gupta AK, Jaiswal SK.
Dipeptidyl peptidase IV inhibitory activity of seed extracts of
Castanospermum austral and molecular docking of their alkaloids.
Topclass J Herb Med 2012;1(1):1-7.
12. Mardanyan S, Sharoyan S, Antonyan A, Zakaryan N. Dipeptidyl
peptidase IV and adenosine deaminase inhibition by 12. Armenian
planta and antidiabetic drugs. Int J Diabetes Metab 2011;19:69-74.
13. Chakrabarti R, Singh B, Narendra P, Varghese N, Vanchhawng L,
Shihabudeen MS, et al. Dipeptidyl peptidase- IV inhibitory activity of
Berberis aristata. J Nat Prod 2011;4:158-63.
14. Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl
peptidase IV (DPP IV) is one of the mechanisms explaining the
hypoglycemic effect of berberine. J Enzyme Inhib Med Chem
15. Singh AK, Jatwa R, Joshi J. Cytoprotective and dipeptidyl peptidase-IV
(DPP-IV/CD26) inhibitory roles of Ocimum sanctum and Momordica
charantia extracts. Asian J Pharm Clin Res 2014;7(1):115-20.
16. Bisht R, Bhattacharya S, Jaliwala YA. Evaluating the use of Desmodium
gangeticum as alpha glucosidase and DPPIV inhibitor for Type-II
diabetes. Am J Phytomed Clin Ther 2014;2(4):530-9.
17. Kilari EK, Mullapudi B, Moka PV, Silakabattini K, Nelli G. Inhibition
of DPP-IV activity and enhancement of GLP-1 expression by aqueous
peel extracts of Punica granatum in albino wistar rats. J Glob Trends
Pharm Sci 2014;5(2):1528-41.
18. Barve K, Bhonsle N. Commiphora mukul prevents myocardial
dysfunction in streptozotocin induced diabetic rats. Pharm Crops
19. Shirazi L, Salehi I, Moradkhani SH. Evaluation of analgesic effects of
clove extracton male offspring of surrey female miceduring lactation.
Armaghane - Danesh 2015;19(10):861-9.
20. Bellamkonda R, Rasineni K, Singareddy SR, Kasetti RB, Pasurla R,
Chippada AR, et al. Anti-hyperglycemic and antioxidant activities of
alcoholic extract of Commiphora mukul gum resin in streptozotocin
induced diabetic rats. Pathophysiology 2011;18(4):255-61.
21. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica
officinalis Gaertn.) on blood glucose and lipid profile of normal subjects
and Type 2 diabetic patients. Int J Food Sci Nutr 2011;62(6):609-16.
22. Nain P, Saini V, Sharma S, Nain J. Antidiabetic and antioxidant potential
of Emblica officinalis Gaertn. leaves extract in streptozotocin-induced
Type-2 diabetes mellitus (T2DM) rats. J Ethnopharmacol
23. Morshed MA, Haque A, Rokeya B, Ali L. Anti-hyperglycemic
and lipid lowering effect of Terminalia arjuna bark extract on
streptozotocin indiced Type 2 diabetic model rats. Int J Pharm Pharm
24. Parveen K, Khan R, Siddiqui WA. Antidiabetic effects afforded by
Terminalia arjuna in high fat-fed and streptozotocin - induced Type 2
diabetic rats. Int J Diabetes Metab 2011;19:23-33
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.